Comparison of Antidepressants Tolerability in Cancer Patients Referred for Psychiatric Consultation.
- Author:
Eunmi KO
;
Jin Seong PARK
;
Juwon HA
;
Sewon LIM
;
Tae Suk KIM
;
Jee Hyun HA
;
Jong Woo PAIK
;
Boung Chul LEE
;
Byeong Moo CHOE
;
Kang Joon LEE
;
Sung Wan KIM
;
Jong Chul YANG
;
Young Hoon KO
;
Kang Seob OH
- Publication Type:Original Article
- Keywords:
Cancer;
Antidepressant;
Tolerablitity;
Consultation
- MeSH:
Antidepressive Agents;
Anxiety;
Citalopram;
Depression;
Hospitals, General;
Humans;
Inpatients;
Korea;
Mianserin;
Paroxetine;
Psychiatry;
Retrospective Studies;
Sleep Initiation and Maintenance Disorders
- From:Korean Journal of Psychosomatic Medicine
2013;21(1):3-10
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Many patients diagnosed with cancer suffer from various psychiatric symptoms such as depression, anxiety and insomnia as well as cancer itself. Patients with cancer are more vulnerable to possible adverse events of psychotropic medications. Although antidepressants are widely used among cancer patients, there is little information about tolerability of antidepressants. This study was conducted to compare tolerability of antidepressants in cancer patients referred for psychiatric consultation. METHODS: The participants were cancer patients who had been referred to psychiatrist for their psychiatric symptoms. We retrospectively analyzed the data of patients diagnosed with cancer from 9 general hospitals in Korea. The discontinuation rate for a 6 months period after treatment initiation for three antidepressants(Escitalopram, Mirtazapine, Paroxetine) were compared. RESULTS: Antidepressants were prescribed for 96.3% of subjects and Escitalopram 150(47.2%), Mirtazapine 92 (28.9%) and Paroxetine 76(23.9%) were prescribed frequently in order There were no significant differences in discontinuation rates among the three antidepressants during the 6 month period after initiation of pharmacotherapy. But there was a difference in discontinuation rates between inpatients versus outpatients(p<0.0001). CONCLUSIONS: In a naturalistic setting for the antidepressant treatment for cancer patients, it seems that there are no differences in discontinuation rates among these three antidepressants. It is therefore essential that such interactions are carefully considered when treating patients of antidepressants who already have cancer.
